A needle-free mRNA vaccine with aluminum phosphate and CpG DNA adjuvants improved immune responses and protected mice against ...
A needle-free vaccination method protected mice against the viruses that cause COVID-19 and flu, offering a possible new way ...
Cambridge-based start-up specialising in synthetic DNA manufacturing for next-generation therapeutics, has raised £15million ...
Delve into Labiotech's October oncology roundup and find out about the news that caught our attention this last month.
GSK has secured US FDA approval for Hibsago in chronic hepatitis B, a first-in-class treatment designed to help patients achieve a functional cure.
The development of sotorasib and adagrasib established that direct KRAS inhibition can produce clinically meaningful responses in KRAS G12C-mutated non-small-cell lung cancer. But those first ...
Researchers engineered hybrid strontium sulfite nanoparticle-modified lipid nanoparticles to deliver p53 mRNA, producing ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced evidence from the OPERA observational cohort spanning five years of real-world ...
最近微信改版，容易找不到尹哥的文章，大家记得把尹哥设为星标⭐️ 哦~ 10 月 20 日，一条消息我盯了很久。 美国 FDA 批准了一款名为Hibsago（贝普若韦生，Bepirovirsen）的注射剂上市。它是第一款获得FDA批准用于慢性乙型肝炎的反义寡核苷酸（ASO）药物，也是第一支真正把“功能性治愈”写进适应证的乙肝药。 这个案例我追了很多年。从早期的二期研究，到今年 5 月 28 日《新英 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results